Senti Bio Positive InitialData in Phase 1 Cell Therapy for Malignancies Including AML

 – 2 of 3 patients achieved MRD negative CR in the first dose level evaluated in the trial with a generally well-tolerated preliminary safety profile –

– Dose escalation is continuing with additional response and durability data expected in 2025 –

– Conference call scheduled on December 3 at 7:30am ET –

Conference Call Information
Senti Bio management and Dr. Strickland will discuss the SENTI-202 results on December 3, 2024 at 7:30am ET. To access the live webcast, please register online on the Events and Presentations page of Senti Bio’s website. The webcast may also be accessed as follows:

Conference ID: 1202759
United States - New York +1.646.968.2525
USA & Canada - Toll-Free +1.888.596.4144
Live webcast: https://edge.media-server.com/mmc/p/q37k42qa 

An archived webcast and accompanying slides will be available on the Company’s website approximately one hour after the event.

https://www.globenewswire.com/news-release/2024/12/02/2989665/0/en/Senti-Bio-Announces-Positive-Initial-Clinical-Data-in-Phase-1-Clinical-Trial-of-SENTI-202-a-Logic-Gated-Selective-CD33-FLT3-Targeting-CAR-NK-Cell-Therapy-for-the-Treatment-of-Relap.html